Jazz Pharmaceuticals
NASDAQ:JAZZBiotechDublin, Ireland, Ireland · Est. 2003 · 2,600 employees
Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines in the fields of neurology, psychiatry, sleep medicine, and oncology.
8
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
9
Indications↗
Distinct diseases across all programs
212
Clinical Trials↗
All sponsored trials (all statuses)
194
Orange Book Patents
Across 20 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
8 drugs in development
Phase 32
Phase 22
Phase 16
By Therapeutic Area
top 2
Oncology
444%
Neurology
222%
R&D Momentum
66/100
Pipeline Velocity
37/100
Trial Completion Rate
77/100
Pipeline Concentration
36/100
Pipeline Freshness
82/100
Strategic Signals
- ↗Active in Neurology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 18, 2026
Recruiting
A Phase 2, Multicenter, Open-Label, Single-Arm Study of Lurbinectedin in Combination With Durvalumab as First-line Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer Following Induction Treatment With Platinum Based Chemotherapy and Durvalumab
Sep 15, 2026
Recruiting
An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer
Sep 15, 2026
8-K
8-K
Sep 11, 2026
Active, not recruiting
Phase 1, FIH, Open-label, Nonrandomized, Multicenter Study of JZP815 in Participants With Advanced or Metastatic Solid Tumors Harboring Alterations in the MAPK Pathway
Earlier
Sep 3, 2026TrialA Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of JZP926 in Participants Aged 10 Years and Older for the Treatment of Juvenile Myoclonic Epilepsy
Sep 2, 2026TrialA Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Sep 1, 2026TrialA Phase 3b/4, Interventional, Prospective, Multicenter, Open-Label Study Evaluating the Effectiveness of a Gradual Titration Regimen to Optimize CBD-OS as Add-On Therapy in Adults With Lennox-Gastaut Syndrome
Aug 31, 20268-K8-K
3 more events
Aug 28, 2026TrialA Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy
Aug 27, 2026TrialA Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
Aug 26, 2026TrialA Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Details
Company Info
Company Overview
$6.5B
Mkt Cap
$376.1M
Revenue
$2.4B
Cash
CEOBruce Cozadd
Founded2003
Employees2,600
HQDublin, Ireland, Ireland
ExchangeNASDAQ:JAZZ
Websitejazzpharmaceuticals.com
LinkedInCompany Page
Therapeutic Focus
OncologyImmunologyHematologyOtherMetabolic & EndocrineCardiovascularInfectious DiseaseNeurologyMusculoskeletalDermatologyGastroenterologyRespiratoryRare DiseaseNephrologyPsychiatryOphthalmology
Recent SEC Filings
8-KSep 15, 2026
8-K
8-KAug 31, 2026
8-K
8-KAug 25, 2026
8-K
8-KAug 10, 2026
8-K
8-KAug 10, 2026
8-K
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Oncology
Neurology
Focal Seizures
CBD-OSPhase 1
Narcolepsy
JZP441Phase 1
Oncology
Advanced Cancer
JZP815Phase 1
Unknown / Other
Paraganglioma
ONC206Phase 2
ONC206: Dose 1Phase 2
Regulatory
Regulatory Timeline
20235 events
FDAOct 11
Robinul — DARTISLA ODT
Application NDA215019 (NDA)
FDASep 8
Aphexda — APHEXDA
Application NDA217159 (NDA)
FDAAug 18
Cymbalta — CYMBALTA
Application NDA021427
FDAAug 18
Cymbalta — CYMBALTA
Application NDA021427
FDAAug 9
Aleve — NAPROXEN SODIUM
Application ANDA214463
20242 events
FDASep 11
Aleve — ALEVE
Application NDA020204
FDAJun 25
Tepadina — TEPYLUTE
Application NDA216984 (NDA)
20256 events
FDAOct 2
Tepadina — TEPADINA AND SODIUM CHLORIDE, TEPADINA
Application NDA208264
FDAJul 23
Anzupgo — ANZUPGO
Application NDA219155 (NDA)
FDAJul 23
Anzupgo — ANZUPGO
Application NDA219155 (NDA)
FDAApr 24
Aleve — ALEVE
Application NDA020204
FDAApr 10
Tepadina — TEPADINA AND SODIUM CHLORIDE, TEPADINA
Application NDA208264
FDAMar 17
Thalitone — HEMICLOR
Application NDA218647 (NDA)
202615 events
SECSep 15
8-K
Accession: 0001628280-26-061978
SECAug 31
8-K
Accession: 0001193125-26-377073
SECAug 25
8-K
Accession: 0001628280-26-058864
SECAug 10
8-K
Accession: 0001193125-26-342667
SECAug 10
8-K
Accession: 0001193125-26-341270
SECAug 3
8-K
Accession: 0001232524-26-000044
SECJul 24
8-K
Accession: 0001628280-26-049466
FDAJun 1
Thiola Ec — TIOCYSTIN
Application NDA212927 (NDA)
FDAMay 27
Trexall — TREXALL
Application ANDA040385
FDAMar 10
Aleve — ALEVE
Application NDA020204
FDAFeb 27
Cymbalta — DULOXETINE HYDROCHLORIDE
Application NDA219131 (NDA)
FDAFeb 27
Cymbalta — DULOXETINE HYDROCHLORIDE
Application NDA219131 (NDA)
SECFeb 24
Jazz Pharmaceuticals plc (JAZZ) (CIK 0001232524)
Accession: 001-33500
FDAJan 15
Tepadina — TEPADINA AND SODIUM CHLORIDE, TEPADINA
Application NDA208264
FDAJan 15
Aleve — NAPROXEN SODIUM
Application NDA021920
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)